Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored

Amgen vs. Celldex: A Decade of Cost Efficiency Compared

__timestamp	Amgen Inc.	Celldex Therapeutics, Inc.
Wednesday, January 1, 2014	4422000000	101881000
Thursday, January 1, 2015	4227000000	4011000
Friday, January 1, 2016	4162000000	102026000
Sunday, January 1, 2017	4069000000	96171000
Monday, January 1, 2018	4101000000	66449000
Tuesday, January 1, 2019	4356000000	42672000
Wednesday, January 1, 2020	6159000000	42534000
Friday, January 1, 2021	6454000000	3068000
Saturday, January 1, 2022	6406000000	1400000
Sunday, January 1, 2023	8415000000	3008000
Monday, January 1, 2024	12858000000

Unveiling the hidden dimensions of data

Exploring Cost Efficiency: Amgen Inc. vs. Celldex Therapeutics, Inc.

In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Amgen Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Amgen's cost of revenue has shown a steady increase, peaking at approximately $8.4 billion in 2023, reflecting a 90% rise from 2014. In contrast, Celldex's cost of revenue has fluctuated significantly, with a notable peak in 2016 and a sharp decline thereafter, reaching a low of around $3 million in 2023. This stark contrast highlights Amgen's expansive operational scale compared to Celldex's more variable cost structure. Understanding these trends provides valuable insights into each company's strategic focus and operational efficiency, offering a window into their financial health and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025